| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 48.724 | 48.414 | 32.788 | 44.373 | 44.923 | 47.908 | 40.024 | 49.146 | 143.677 | 224.366 |
| Total Income - EUR | 48.725 | 48.414 | 32.789 | 44.589 | 44.924 | 47.909 | 40.025 | 49.178 | 143.806 | 226.051 |
| Total Expenses - EUR | 56.394 | 49.377 | 35.883 | 31.216 | 27.504 | 31.136 | 37.029 | 28.896 | 27.293 | 51.552 |
| Gross Profit/Loss - EUR | -7.670 | -963 | -3.094 | 13.373 | 17.419 | 16.773 | 2.995 | 20.282 | 116.513 | 174.499 |
| Net Profit/Loss - EUR | -9.132 | -1.447 | -3.422 | 12.929 | 16.970 | 16.294 | 2.723 | 19.800 | 115.105 | 169.145 |
| Employees | 9 | 9 | 7 | 4 | 4 | 4 | 5 | 3 | 2 | 2 |
Check the financial reports for the company - Phasmatis Med Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 179 | 44 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.576 |
| Current Assets | 5.690 | 8.640 | 14.141 | 26.897 | 19.094 | 27.086 | 32.740 | 42.276 | 156.687 | 168.780 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 4.247 | 8.223 | 13.996 | 24.356 | 12.933 | 7.845 | 9.631 | 33.788 | 112.894 | 114.197 |
| Cash | 1.443 | 417 | 145 | 2.540 | 6.161 | 19.241 | 23.108 | 8.488 | 43.793 | 54.583 |
| Shareholders Funds | -26.872 | -28.044 | -30.991 | -17.493 | -184 | 16.845 | 19.194 | 19.840 | 115.146 | 169.209 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 32.741 | 36.729 | 45.132 | 44.390 | 19.279 | 10.241 | 13.546 | 22.435 | 41.541 | 10.147 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "5812 - 5812" | |||||||||
| CAEN Financial Year |
5813
|
|||||||||
Comments - Phasmatis Med Srl